## 73. IPT: attitudes, application and adherence Sunday, 06 December 2015, 12:15-13:15

Chair: Neil MARTINSON (South Africa)

Track: HIV and TB co-infection

PC-1318-06	Predicting development of active tuberculosis in dialysis patients by serial follow-up of latent tuberculous infection
	C-C- Shu, J-Y- Wang, V-C Wu, F-J Yang, C-J- Yu, L-N Lee (Taiwan)
PC-1319-06	Perceptions and knowledge of health care workers plays a role in increasing isoniazid preventive therapy uptake amongst people living with HIV
	M Calnan, M Pasipamire, S Mazibuko, S Haumba, N Shongwe (Swaziland)
PC-1320-06	Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi
	K Little, G Barnes, M Khundi, L G Ngwira, R E Chaisson, A Nkhoma, L Corbett, D Dowdy (USA, UK)
PC-1321-06	Population-level impact of different durations of isoniazid preventive therapy among people living with HIV
	A Kunkel, F Crawford, T Cohen (USA)
PC-1322-06	Biologic anti-rheumatoid agents alter interferon-gamma release assay results for detection of latent tuberculous infection
	W Thanassi, J Chang, J Sokolove (USA)
PC-1323-06	Improving implementation of isoniazid preventive therapy through community-based referral in rural South Africa
	S Shenoi, Ap Moll, T Van Der Merwe, P Vranken, L Andrews, Rp Brooks, Ek Dokubo, G Friedland (USA, South Africa)
PC-1324-06	Impact of pregnancy on latent tuberculous infection diagnostics in HIV-infected pregnant women in western Kenya
	S Lacourse, L Cranmer, D Matemo, J Kinuthia, D Horne, G John-Stewart (USA)
PC-1325-06	Tuberculosis screening and isoniazid Preventive therapy provision among patients initiating antiretroviral therapy, Nigeria, 2004–2012
	I Pathmanathan, Ek Dokubo, S Ray, D Onotu, S Odafe, I Dalhatu, H Debem, S Agolory (USA)
PC-1326-06	Modelling the post-treatment effect of isoniazid plus antiretroviral therapy on tuberculosis incidence
	T Sumner, R Houben, G Maartens, M Rangaka, R White (UK, South Africa)